Atossa Therapeutics Faces Delisting Concerns
Ticker: ATOS · Form: 8-K · Filed: Aug 21, 2025 · CIK: 1488039
| Field | Detail |
|---|---|
| Company | Atossa Therapeutics, INC. (ATOS) |
| Form Type | 8-K |
| Filed Date | Aug 21, 2025 |
| Risk Level | high |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.18, $1.00 |
| Sentiment | bearish |
Sentiment: bearish
Topics: delisting, listing-standards, regulatory-filing
TL;DR
Atossa's 8-K flags potential delisting issues - stock might be in trouble.
AI Summary
Atossa Therapeutics, Inc. filed an 8-K on August 21, 2025, to report a notice of delisting or failure to satisfy a continued listing rule or standard. The company is based in Seattle, Washington, and its fiscal year ends on December 31st. This filing indicates potential issues with maintaining its stock exchange listing.
Why It Matters
This filing signals potential difficulties for Atossa Therapeutics in meeting stock exchange listing requirements, which could impact its stock's tradability and investor confidence.
Risk Assessment
Risk Level: high — A notice of delisting or failure to meet listing standards is a significant negative event that can severely impact a company's stock and operations.
Key Numbers
- 20250821 — Filing Date (Indicates the report was filed on this date.)
- 1231 — Fiscal Year End (Defines the company's financial year-end.)
Key Players & Entities
- Atossa Therapeutics, Inc. (company) — Registrant
- August 21, 2025 (date) — Date of earliest event reported
- Seattle, Washington (location) — Principal Executive Offices
- Delaware (location) — State of Incorporation
- 001-35610 (other) — Commission File Number
FAQ
What specific listing rule or standard has Atossa Therapeutics failed to satisfy?
The filing does not specify the exact rule or standard that Atossa Therapeutics has failed to satisfy, only that a notice of delisting or failure to satisfy a continued listing rule or standard has been issued.
What is the immediate impact of this 8-K filing on Atossa Therapeutics' stock?
This 8-K filing signals potential delisting, which typically leads to increased volatility and negative investor sentiment for the stock.
Has Atossa Therapeutics provided any plan to regain compliance with listing standards?
The provided text of the 8-K filing does not contain information about a plan to regain compliance with listing standards.
When was Atossa Therapeutics, Inc. incorporated?
Atossa Therapeutics, Inc. was incorporated in Delaware, as indicated by the filing.
What is the company's principal executive office address?
The company's principal executive offices are located at 10202 5th Avenue NE, Suite 200, Seattle, Washington, 98125.
Filing Stats: 536 words · 2 min read · ~2 pages · Grade level 13.3 · Accepted 2025-08-21 16:05:28
Key Financial Figures
- $0.18 — ge on which registered Common Stock , $0.18 par value ATOS The Nasdaq Capital M
- $1.00 — maintain a minimum closing bid price of $1.00 per share for 30 consecutive business d
Filing Documents
- atos-20250821.htm (8-K) — 45KB
- 0000950170-25-110654.txt ( ) — 154KB
- atos-20250821.xsd (EX-101.SCH) — 28KB
- atos-20250821_htm.xml (XML) — 5KB
01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On February 21, 2025, Atossa Therapeutics, Inc. (the "Company") received a letter (the "Notice") from The Nasdaq Stock Market LLC ("Nasdaq") informing the Company that it was not in compliance with the minimum bid price requirements set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on Nasdaq, because the Company's common stock failed to maintain a minimum closing bid price of $1.00 per share for 30 consecutive business days. The Company's initial compliance period ended on August 20, 2025, and the Company subsequently requested an extension. On August 21, 2025, the Company was informed that its deadline to regain compliance was extended by 180 days, or until February 17, 2026 The Notice has no immediate effect on the listing or trading of the Company's common stock on Nasdaq. The Company intends to actively monitor the bid price for its common stock, and is committed to considering available options to regain compliance with the minimum bid price requirement, including, if necessary, potentially effectuating a reverse stock split. * * *
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Atossa Therapeutics, Inc. Date: August 21, 2025 By: /s/ Heather Rees Heather Rees Chief Financial Officer